INTRODUCTION
Within the majority of cells exist two dynamic organellar networks establishing the endoplasmic reticulum (ER) and mitochondria (Gardner et al., 2013; Hoppins and Nunnari, 2012) . The ER network is comprised of interconnected tubules that are essential for the translation, folding, and transport of nascent polypeptides that are destined for transmembrane localization and/or secretion (Blobel, 2000) . The mitochondrial network is also comprised of interconnected tubules but is essential for cellular respiration, Ca 2+ homeostatis, and the regulation of apoptosis (Youle and van der Bliek, 2012) . While the two networks serve distinct functions, the ER and mitochondria are biophysically and biochemically associated via proteinaceous tethers and lipid microdomains that are implicated in cellular signaling (Csordá s et al., 2006; de Brito and Scorrano, 2008; Hoppins and Nunnari, 2012) .
Signaling between the organelles is highlighted by the use of drugs that disrupt homeostasis within the ER network and promote apoptosis. Beta-mercaptoethanol (b-ME), dithiothreitol (DTT), thapsigargin (Tg), and tunicamycin (Tun) promote ER stress by impinging upon disulphide bond formation within the ER lumen (b-ME and DTT), inhibiting N-glycosylation of nascent ER proteins (Tun), or by disrupting ER luminal Ca 2+ stores (Tg) (Dorner et al., 1990; Price et al., 1992) . These agents activate a series of cytoplasmic and nuclear signaling events referred to as the unfolded protein response (UPR) (Gardner et al., 2013) . A marker of the UPR is the accumulation of 78 kDa glucose-regulated protein/binding immunoglobulin protein (BiP), which serves as a chaperone within the ER lumen to assist in protein stability, folding, assembly, and transport (Hendershot, 2004; Otero et al., 2010) .
If the UPR cannot be resolved or is prolonged, the cytoprotective nature of the UPR is switched to pro-death signaling (referred to as the ''terminal UPR'' or ''tUPR'') by increasing the translational efficiency of the transcription factor C/EBP homologous protein (CHOP), and this leads to the expression of proteins that lower the apoptotic threshold (Harding et al., 2000; Lin et al., 2007; Puthalakath et al., 2007; Scheuner et al., 2001) . Proapoptotic BCL-2 proteins are transcriptionally and/or posttranslationally induced following UPR, including BCL-2-interacting mediator of cell death (BIM) and p53 upregulated modulator of apoptosis (PUMA) (Ghosh et al., 2012; Puthalakath et al., 2007) . These BCL-2 proteins belong to a subset of proapoptotic proteins referred to as BH3-only proteins, as they possess only one conserved BCL-2 homology (BH) region within the BCL-2 family, referred to as the BH3 domain (Chipuk et al., 2010; Kuwana et al., 2005; Letai et al., 2002) . BIM and PUMA function by interacting with the other BCL-2 family subsets: the antiapoptotic BCL-2 proteins (e.g., BCL-xL), which preserve survival, and the proapoptotic effector proteins (e.g., BAK, BAX), which are required for cytochrome c (cyto c) release and the induction of apoptosis . While PUMA and BIM are both induced following UPR, each protein likely has unique biochemical functions to promote BAK/BAX-mediated apoptosis Kuwana et al., 2005; Letai et al., 2002) .
Recent literature suggests that ER-mitochondrial communication regulates multiple aspects of cell biology, including mitochondrial dynamics, which is responsible for maintaining optimal mitochondrial function by balancing the fusion and fission of the mitochondrial network (Hoppins and Nunnari, 2012; Youle and van der Bliek, 2012) . Mitochondrial dynamics is regulated by a set of large GTPases that are found in mitochondrial membranes; the most critical proteins are mitofusins 1 and 2 (Mfn1/ 2) and optic atrophy 1 (OPA1), which cause fusion, and dynamin related protein 1 (DRP1), which promotes fission (Martinou and Youle, 2011) . When a cell's mitochondrial network becomes either hyperfused or hyperfragmented, there are metabolic disruptions and collateral negative influences on the mitigation of UPR and cellular fitness. For example, Mfn2 loss perturbs mitochondrial homeostasis through altered inner mitochondrial membrane function and stress signaling, and this sensitizes to UPR (Ngoh et al., 2012) . It is established that stress-induced apoptosis proceeds via collaborative efforts between the BCL-2 family and mitochondria, yet mechanisms related to how mitochondrial network shape itself impacts upon cell death commitment remain unknown.
Here, we investigated the requirements and collaborations between UPR-induced proapoptotic BCL-2 proteins and mitochondrial shape. Utilizing a panel of mouse embryonic fibroblasts (MEFs), small-molecule regulators of the BCL-2 family and mitochondrial dynamics, and biochemically defined outer mitochondrial membrane (OMM) model systems, our data reveal a direct contribution of mitochondrial shape in mediating BAX-dependent MOMP. Specifically, OMM diameter cooperates with BAX alpha helix 9 (a9) to mediate stable BAX$membrane interactions, MOMP, and efficient tUPR resolution. We also observed similar requirements for mitochondrial shape in sensitizing MEFs and cancer cells to conventional chemotherapeutics.
RESULTS
BAX, BIM, and PUMA Mediate tUPR Our study was initiated by systematically examining the contributions of distinct subsets of proapoptotic BCL-2 proteins in tUPR. This was achieved by treating genetically matched transformed MEFs with the ER stress-inducing agents: b-ME, DTT, Tg, and Tun. We first examined a requirement for BAK and BAX. Wild-type (WT) , and Bax À/À MEFs. As shown in Figure 1E , the majority of tUPR required Bax, as deletion of Bak had minimal impact. Indeed, WT, Bak À/À , and Bax À/À MEFs responded similarly to UPR induction ( Figure 1F ). As Bax is genetically required for inducing tUPR in MEFs, we next investigated if BAX was activated in this scenario by the use of an antibody that specifically recognizes the activated conformation of BAX (clone 6A7) (Hsu and Youle, 1997) . WT MEFs were treated with the UPR agents for 18 hr, and lysates were subjected to 6A7 immunoprecipitation (IP). Indeed, each drug led to a marked increase in 6A7-recognized activated BAX, and not a general induction of BAX expression ( Figure 1G ). BAX oligomerization is another measure of activation, and mitochondria-associated BAX oligomers are resistant to trypsin digestion (Lucken-Ardjomande et al., 2008) . Therefore, we treated WT MEFs with the UPR drugs for 18 hr, isolated mitochondria, and assayed for trypsin-resistant BAX. Indeed, mitochondrial-associated, trypsin-resistant BAX was detected in cells treated with the drugs ( Figure 1H ). These observations suggest that the proapoptotic effector BAX is activated after ER stress and is responsible for subsequent tUPR. BAX is constitutively expressed in most cells, so its proapoptotic function must be turned on in order for apoptosis to proceed (Chipuk et al., 2010) . This is usually achieved by interactions with a subset of the proapoptotic BCL-2 family, the direct activator BH3-only proteins, e.g., BID and BIM (Kuwana et al., 2005; Letai et al., 2002; Wei et al., 2000) . Genetic deletion of Bid does not result in any observable resistance to tUPR ( Figures  S2A-S2D ), but Bim is described to be transcriptionally induced following UPR (Puthalakath et al., 2007) . As interpretations of our future biochemical studies could be confounded by the presence of BID, we chose to evaluate the requirement for BIM in the absence of BID using Bid
Bim
À/À MEFs. Using the same UPR inducers and apoptosis assay in Figures 1A-1D , Bid
MEFs demonstrated an appreciable resistance to all drugs , despite significant BiP and CHOP inductions ( Figures S2H-S2K ).
To ensure that BIM was engaged following the UPR, we examined if BIM isoforms (BIM-S, BIM-L, and BIM-EL) were induced in WT MEFs. Western blot revealed only modest inductions of BIM-EL ( Figure S2L ). However, in order for BIM to activate BAX, BIM should be present at the OMM; therefore, we next investigated the accumulation of BIM isoforms on the OMM following UPR. In contrast to data presented in Figure S2L , multiple BIM isoforms accumulated on the OMM and were easily detected ( Figure 1J ). To examine the potential function of the OMM-accumulated BIM isoforms, we investigated if derepression of BIM from BCL-2/ BCL-xL could promote cyto c release in vitro. To induce BIM derepression, we added ABT-737, a small-molecule inhibitor to BCL-2/BCL-xL, to the isolated mitochondria from ER stressed cells and assayed for BIM-dependent cyto c release (Oltersdorf et al., 2005) . Indeed, ABT-737 treatment revealed BIM-dependent cyto c release only with mitochondria isolated from ER stressed cells ( Figure 1K ). These data suggest that all UPR agents induce the expression and mitochondrial accumulation of active BIM. , and Bax À/À MEFs were treated with b-ME (15 mM), DTT (5 mM), Tg (1.5 mM), or Tun (2.5 mg/ml) for 18 hr.
(F) Lysates from ER stress-treated WT, Bak
, and Bax À/À MEFs in (E) were analyzed by western blot.
(G) CHAPS lysates from ER stress-treated WT MEFs (highest doses at 18 hr) were subjected to 6A7 IP and western blot. Total cell lysates (5%) were analyzed as a loading control. (H) HM fractions isolated from ER stress-treated WT MEFs (highest doses at 18 hr) were subjected to trypsinization and analyzed by western blot. Total cell lysates (5%) were analyzed as a loading control for BAX; VDAC is a pretrypsinization mitochondrial loading control. (N) Puma À/À MEFs were pretreated either with ABT-737 (1 mM) for 1 hr and then b-ME for 18 hr or with b-ME for 18 hr and then ABT-737 for an additional 6 hr.
(O) A summary schematic of BCL-2 family interactions required for apoptosis to proceed. All data are representative of at least triplicate experiments and reported as ±SD, as required. See also Figures S1-S3.
BIM functions optimally when additional sensitizer/derepressor BH3-only proteins are induced, e.g., PUMA Garrison et al., 2012; Kuwana et al., 2005) . PUMA functions as a sensitizer/derepressor BH3-only protein in vivo and in isolated primary human cancer cells (Certo et al., 2006; Chipuk et al., 2008; Del Gaizo Moore et al., 2007) . Likewise, Puma expression can be positively regulated following ER dysfunction (Ghosh et al., 2012; Puthalakath et al., 2007; Reimertz et al., 2003) . To examine a requirement for PUMA in our model systems, we first determined if PUMA was induced following UPR. After WT MEFs were treated with the ER stress drugs for 18 hr, mitochondria were isolated and assayed for PUMA accumulation by western blot; all forms of ER stress caused PUMA to accumulate on the OMM ( Figure 1L) BCL-2/xL before stress signaling) or after ER stress treatment (i.e., derepressing accumulated proapoptotic signaling from BCL-2/xL). For these assays, we examined b-ME, as Puma À/À MEFs were most resistant to this drug . Pretreatment with ABT-737 before or after b-ME addition markedly enhanced tUPR in Puma
MEFs, indicating that exogenous addition of sensitization/derepression function rescues apoptotic resistance ( Figure 1N ). Together, these data suggest that UPR-induced PUMA is required to derepress the function of BIM to activate BAX ( Figure 1O ) and that pharmacological sensitization/derepression replaces the genetic requirement for Puma.
UPR Promotes BIM, PUMA, and Mfn1 Accumulation at the OMM In Vivo Next, we implicated BIM and PUMA in UPR signaling in vivo. WT mice were injected with Tun, sacrificed 24 hr later, then livers were resected and subjected to total RNA, protein, and mitochondria isolations. As performed in cultured cells earlier (e.g., Figure 1F ), we analyzed the livers for UPR markers, and BiP and CHOP were markedly induced at the mRNA ( Figure 2A ) and protein levels ( Figure 2B ). We then analyzed liver wholecell extracts from Tun-injected animals for the expression of BIM and PUMA by western blot. Indeed, all three isoforms of BIM and PUMA were induced ( Figure 2C ). To determine the localization of BIM after ER stress induction in vivo, we isolated mitochondria from the livers of Tun-injected animals and analyzed them by western blot. As shown in Figure 2D , BIM-L and BIM-S were readily detectible in mitochondrial fractions, and nearly 100% of the detectible BIM-L and BIM-S was displaced from the mitochondrial pellet by coincubation with PUMA, suggesting that BIM-S and BIM-L were bound to antiapoptotic BCL-2 proteins.
As mitochondria and ER communicate via membrane tethering and a series of signaling events (i.e., induced expression of BIM and PUMA; Figures 1J and 1L ), to induce tUPR we evaluated the expression of Mfn1 and Mfn2, which are implicated in ER-mitochondrial communication. We isolated liver mitochondria from animals exposed to Tun and subjected mitochondrial protein lysates to western blot ( Figure 2E ). Mfn1 was more abundant in mitochondrial fractions from Tun-treated animals compared to PBS controls, and the increase in Mfn1 at the OMM is likely due to an UPR-induced transcriptional induction of Mfn1 ( Figure 2F ). While Mfn2 is regulated following UPR in transformed fibroblasts ( Figure S4A ), we did not observe a requirement for Mfn2 in sensitivity to UPR ( Figures S4B-S4E ) and did not detect a change in mRNA or protein in liver (Figures 2E and 2F) (Ngoh et al., 2012 S4M ) and corrected the mitochondrial fragmentation phenotype ( Figure S4N ). To gain mechanistic insights that explain how Mfn1 À/À MEFs resist tUPR, we compared and validated the shape of the mitochondrial networks in the WT, Mfn2
, and Mfn1 À/À MEFs (Figure 3B) . WT cells displayed a normal mitochondrial network, whereas Mfn2 deletion resulted in a swollen, short tubular network. In contrast, Mfn1 loss resulted in a hyperfragmented spherical network ( Figure 3B ). All of the above are consistent with the phenotypes obtained in the murine models of Mfn1 and Mfn2 deletion (Chen et al., 2003) . We hypothesized that these alterations in mitochondrial shape directly impact on the function of proapoptotic BCL-2 proteins. To examine this, we pharmacologically inhibited DRP-1 with the small molecule mDIVI-1 to enhance mitochondrial fusion in the Mfn1 À/À MEFs and then evaluated sensitivity to tUPR (Cassidy-Stone et al., 2008) . Indeed, the addition of mDIVI-1 to Mfn1 À/À MEFs increased mitochondrial network connectively and decreased the small spherical phenotype commonly associated with Mfn1 deletion ( Figure 3C ). The average mitochondrial size after mDIVI-1 treatment was enhanced approximately 5-fold, increasing from 0.42 mm to 2.21 mm ( Figure 3C ), which approaches mitochondria in WT MEFs (2.76 mm ± 1.4 mm). We next determined if mDIVI-1-enhanced mitochondrial fusion resensitized cells to tUPR. mDIVI-1 pretreatment revealed dosedependent enhancement of DTT-induced apoptosis in the Mfn1 À/À MEFs ( Figure 3D ) and also resensitized to Tg-and Tun-induced apoptosis ( Figures 3E and 3F ). While mDIVI-1 cooperated with inducers of the UPR, this was not extended to an inducer of the extrinsic apoptotic pathway ( Figure 3G ). As a control for mDIVI-1 sensitization, we silenced Drp1 expression in Mfn1 À/À MEFs by RNAi, and this led to similar increases in mitochondrial fusion and enhanced tUPR ( Figures S4O  and S4P ). Finally, to examine if OPA1-mediated mitochondrial hyperfusion also regulated apoptosis, WT MEFs expressing exogenous OPA1 were treated with DTT or Paclitaxel. Indeed, OPA1-induced hyperfusion led to an approximately 50% decrease in apoptosis ( Figure S4Q ); however, a reciprocal loss-of-function experiment with OPA1 could not be performed because Opa1 silencing alone was sufficient to generate a proapoptotic signal in cells, as expected ( Figure S4R ) (Cogliati et al., 2013 Figure 3H ), yet displayed resistance to tUPR ( Figures 3A, S4F , and S4G). Resensitization to tUPR was achieved by mDIVI-1 treatment in Mfn1 À/À MEFs ( Figures 3D-3F) ; therefore, we determined if BAX accumulation was induced following ER stress treatment in an mDIVI-1-dependent manner. Mitochondria isolated from cells treated with ER stress agents or mDIVI-1 alone displayed minimal BAX accumulation, yet cotreatment revealed rapid, marked accumulation of monomeric BAX and high molecular weight BAX complexes, presumably BAX dimers and oligomers ( Figure 3I ). We evaluated the expression of multiple antiapoptotic and proapoptotic BCL-2 family members to ensure mDIVI-1 did not influence their levels ( Figure 3J ). We also performed an additional experiment showing that mDIVI-1 pretreatment in WT MEFs results in a loss in sensitivity to DTT-, Tg-, and Tun-induced apoptosis, as expected ( Figure 3K ) (Cassidy-Stone et al., 2008) . Reconnection of the Mfn1 À/À mitochondrial network with mDIVI-1 should have a broad impact on cellular sensitivity to proapoptotic agents beyond the UPR pathway. Therefore, we tested if mDIVI-1 resensitized Mfn1 À/À MEFs to Paclitaxel (microtubule destabilizer) or cisplatin (DNA damaging agent). Indeed, pretreatment with mDIVI-1 markedly sensitized Mfn1
MEFs to apoptosis induced by either Paclitaxel or cisplatin (Figure 3L ). Increased sensitization to apoptosis was also observed in the human melanoma cell line, A375, which displays hyperfragmented mitochondria ( Figures 3M and 3N ). Reconnecting Mfn1 À/À mitochondria promoted mitochondrial BAX accumulation and tUPR, leading us to question whether mitochondrial shape itself influences productive interactions between proapoptotic BCL-2 family members leading to MOMP. In the upcoming sets of experiments, we studied the functional interactions between proapoptotic BCL-2 family members and various mitochondrial membrane shapes using a combination of model systems that faithfully recapitulate BCL-2 family function, the OMM, and MOMP Certo et al., 2006; Kushnareva et al., 2012; Kuwana et al., 2002) .
Mitochondrial Size Dictates Sensitivity to BAX-Dependent MOMP In Vitro and In Cellulo
The fundamental ability of BAX to permeabilize mitochondria in the absence of direct activator stimulation is studied by incubating mitochondria with supraphysiological concentrations of BAX. To directly examine the response of mDIVI-1-treated Mfn1 À/À mitochondria to BAX, we performed a modified version of BH3 profiling (Ryan and Letai, 2013) , where instead of adding BH3 domain peptides to JC-1 loaded, digitonin-permeabilized whole cells, we added either monomeric BAX (i.e., not activated) or n-octyl-b-glucoside-treated BAX (BAX OG ; n.b., this treatment activates BAX). In this assay, the time-dependent decay of JC-1 fluorescence (i.e., Dc M ) is directly correlated with MOMP ( Figure 4A ).
As shown in Figure 4 , Mfn1 À/À cells pretreated with DMSO and then BAX demonstrated $25% MOMP, whereas mDIVI-1 (E and F) Mfn1 À/À MEFs were pretreated with mDIVI-1 (25 mM) for 8 hr, then Tg (0.25 mM) (E) or Tun (0.5 mg/ml) (F) for 18 hr.
(G) Mfn1 À/À MEFs were pretreated with mDIVI-1 (25 mM) for 8 hr, then TNFa and CHX (10 mg/ml) for 18 hr.
(H) HM fractions from ER stress-treated Mfn1 À/À MEFs were analyzed by western blot.
(I) Mfn1 À/À MEFs were pretreated with mDIVI-1 (25 mM) for 2 hr and ER stress agents for 18 hr, and mitochondria were isolated and analyzed by western blot. High molecular weight complexes of BAX are indicated (*). VDAC is a loading control. (J) Mfn1 À/À MEFs were treated with mDIVI-1 (25 mM) for 8 hr, and lysates were analyzed by western blot.
(K) WT MEFs were pretreated with mDIVI-1 (25 mM) for 8 hr and ER stress agents for 18 hr. 4C ). In contrast, BAX OG treatment led to similar extents of permeabilization, presumably because BAX was activated in vitro ( Figures 4B and 4C) . FCCP maximally uncouples respiration from mitochondrial ATP production and establishes the maximal change in Dc M and JC-1 fluorescence. A more physiologically relevant scenario is to examine how direct activators promote BAX-mediated permeabilization. Taking advantage of recently published work demonstrating that BIM preferentially promotes BAX-mediated MOMP (Sarosiek et al., 2013) , we next examined the efficiency by which BIM-S affected MOMP in Mfn1
À/À cells treated with mDIVI-1. Similar to above, Mfn1 À/À cells pretreated with DMSO and then BIM-S demonstrated weak permeabilization compared to mDIVI-1 pretreatment, which resulted in nearly $80% MOMP in most cases ( Figures 4D and 4E ). We could not rule out unknown changes to mitochondrial composition or off-target effects caused by mDIVI-1 pretreatment. Therefore, we isolated C57Bl/6 liver heavy membrane (HM) fractions and subjected the purified HMs to gravity flow CL-2B column chromatography to fractionate by size and then examined the efficiency of BAX and BAX OG to permeabilize the different HM populations. Prior to fractionation, JC-1 was loaded into mitochondria, and this was used (1) to detect fractions containing mitochondria, (2) to ensure equal mitochondrial loading between mitochondrial populations, and (3) as a realtime kinetic marker for MOMP similar to the whole-cell experiments in Figures 4B-4E . An example fractionation is shown in Figure 4F , and relationships to two different-sized large unilamellar vesicles (LUVs) are indicated. We then categorized the fractionated HMs into >0.5 mm (fractions 6-8) and <0.5 mm (fractions 11-15). Nearly all of the >0.5 mm mitochondria responded to BAX-mediated permeabilization, but the smaller <0.5 mm mitochondria greatly resisted BAX; again, both large and small sizes of mitochondria responded equally to BAX OG with $100% MOMP ( Figures 4G and 4H ). To ensure that this observation was relevant to direct activator-mediated BAX permeabilization, we repeated the above scenario, but with Bak À/À liver mitochondria, and supplemented BAX and BIM-S. Figure 4I shows an example fraction profile (>0.5 mm, fractions 8-10; <0.5 mm, fractions 12-16); and indeed, smaller mitochondria demonstrated marked resistance to BAX alone and BIM plus BAX (Figures 4J and 4K) . We evaluated the expression of multiple antiapoptotic and proapoptotic BCL-2 family members by western blot to ensure that there were no marked differences between large and small mitochondria ( Figures S5A and S5B ). We confirmed that the bioenergetics of large and small mitochondria were similar by JC-1 and TMRE staining ( Figures S5C and S5D) and that JC1 or TMRE staining did not influence permeabilization ( Figure S5E ).
Mitochondrial Membrane Diameter Specifically Functionalizes BAXa9 to Promote Membrane Permeabilization
To mechanistically interrogate the functional contribution of mitochondrial shape in promoting BAX-mediated MOMP, we employed two biochemical OMM model systems: outer membrane vesicles (OMVs) and LUVs. OMVs are generated by removing the OMM from freshly isolated rat liver mitochondria, which leads to spontaneous resealing of the OMM and nearphysiological maintenance of OMM environment and function ) ( Figure 5A ). As recently reported, OMVs demonstrate rapid permeabilization when incubated with BAX and direct activator proteins (i.e., N/C-BID) or peptides (i.e., BIM BH3) ( Figures 5B and 5C ). OMV diameters range between 0.7 and 0.8 mm, and this does not change following BAX association or permeabilization ( Figures S6A and S6B) . We then generated a panel of OMVs via extrusion through polycarbonate filters (i.e., 0.05, 0.2, and 1.0 mm pore size) to yield distinct OMV diameters that represent mitochondrial sizes commonly observed in isolated primary liver mitochondrial preparations ( Figures 4F and 4I ). To ensure that the OMVs were appropriately sized and not damaged due to processing, we performed dynamic light scattering (DLS), and the resulting size distributions and recovery were ideal ( Figures 5D-5F ). As OMVs are normally $0.75 mm, the 1 mm pore filters were used as a processing control, yet 1 mm pore extrusion did reduce OMV size to $0.6 mm ( Figure 5D ). We define and label OMVs by filter pore size: 0.05, 0.2, and 1.0 mm.
Similar to data presented in Figures 4B-4C , 4G, and 4H, supraphysiological concentrations of monomeric BAX preferentially permeabilized larger OMVs in a time-dependent manner ( Figure 5G ). Likewise, BAX activation mediated by BIM ( Figures  5H, S6C , and S6D) and BID ( Figures 5I, S6E , and S6F) also demonstrated a size-dependent permeabilization preference, and the influence of membrane diameter was most dramatic for BIM-mediated BAX activation.
Thus far, our findings show that PUMA-mediated derepression of BIM promotes BAX activation in cells to initiate tUPR; therefore, we biochemically modeled this derepression scenario to determine a mitochondrial shape requirement. This was examined by combining BAX and BIM, which resulted in OMV permeabilization ( Figure 5J, left) , adding BCL-xL to inhibit this activity ( Figure 5J , middle) and then adding PUMA BH3 peptide to derepress the effects of BCL-xL leading to BAX-dependent membrane permeabilization ( Figure 5J, right) . In all BCL-2 family combinations, the 0.2 mm and 0.05 mm LUVs demonstrated significantly reduced permeabilization compared to the larger LUVs. The OMV data also suggest that mitochondrial subcomparments do not influence the preferences for membrane diameter.
LUVs comprised of phospholipids ( Figure 6A ) that parallel the composition of mitochondrial membranes are permeabilized by the cotreatment with nanomolar concentrations of BAX and a direct activator protein, such as BID or BIM ( Figure 6B ) . To examine the influence of membrane shape on the function of BAX to permeabilize a defined membrane in the absence of proteins, we generated LUVs via extrusion through polycarbonate membranes of varying pore sizes: 0.05, 0.2, and 1.0 mm (Figures 6C-6E ). Our method of LUV production normally results in a LUV diameter equal to $0.8 mm; therefore, the 1 mm pore filters were used as a processing control similar to the OMVs above, yet 1 mm pore extrusion did reduce LUV size to $0.6 mm ( Figure 6C ). We also define and label LUVs by filter pore size. Similar to the previous cellular and OMV experiments, high concentrations of BAX preferentially permeabilized LUVs greater than 0.2 mm in diameter ( Figure 6F ). Likewise, BAX activation mediated by BIM ( Figures 6G and S7A ) and BID ( Figures  6H and S7B ) also demonstrated a size-dependent permeabilization preference. To corroborate these findings, we also examined direct activator-induced BAX association with LUVs. BAX, BID/BIM, and LUVs were coincubated for 1 hr, the LUVs were pelleted, and associated BAX was determined by western blot. BID and BIM induced optimal BAX association with 0.2 mm and 1.0 mm LUVs, whereas 0.05 mm LUVs accumulated minimal BAX before or after direct activator stimulation ( Figure 6I ). Similar to OMVs, small LUVs also resisted PUMA-mediated derepression of BIM to promote BAX activity ( Figure 6J) .
To understand the mechanism linking mitochondrial membrane diameter and BAX function, we first examined if BAX OG ( Figure S7C ) demonstrated membrane preferences. As shown in Figure 7A , BAX OG permeabilized LUVs independent of diameter, suggesting that postactivation events do not demonstrate membrane preferences. BH3-only protein-induced BAX activation is associated with amino and carboxy-terminal rearrangements prior to membrane permeabilization, which are measured by 6A7 positivity and membrane association, respectively. To determine if membrane diameter influences 6A7 positivity, we incubated BAX ± BIM in the presence of 0.05, 0.2, and 1.0 mm LUVs. Previous reports demonstrate that LUVs can promote transient 6A7 positivity independent of BH3 stimulation (Yethon et al., 2003) , and we observed similar responses for 0.2 and 1 mm LUVs ( Figure 7B ). More importantly, while 0.05 mm LUVs fail to promote marked 6A7 positive BAX alone, these LUVs supported 6A7 positive BAX in the presence of BIM similar to 1 mm LUVs, suggesting that amino-terminal events were not inhibited ( Figure 7B ).
The carboxy-terminal hydrophobic trans-membrane a9 region of monomeric BAX must be mobilized and displaced from the globular helical core of BAX in order for membrane permeabilization to proceed. A BAX mutant lacking a9 (BAX DC ) supersedes these requirements; therefore, we next determined if BAX DC demonstrated membrane preferences. Despite requiring a longer incubation time compared with BAX WT (Figure S7D ), the rate and extent of BAX DC -mediated permeabilization were nearly identical for all LUV diameters ( Figure 7C ). These data suggested that BAX a9 function was the critical step of permeabilization regulated by membrane diameter.
To determine if a carboxy-terminal rearrangement leading to membrane association is the key feature of BAX activation that demonstrates a membrane shape requirement, we compared BAX WT and a BAX mutant (BAX S184A ) that is constitutively membrane associated due to a point mutation in BAX a9 (Nechushtan et al., 1999 ), yet not activated ( Figures 7D and 7E) . Our previous data demonstrate that BAX associates with LUVs in a BH3-only protein and LUV diameter-dependent manner ( Figure 7B ). In contrast to BAX WT , BAX S184A did not display a significant preference for LUV diameter, which was determined by coincubation followed by western blot ( Figure 7F) ; and comparing NBDlabeled BAX WT and BAX S184A for basal and BH3-only proteininduced membrane association confirmed this result ( Figure 7G ). These data suggested that membrane diameter specifically regulates BAX a9 release, but not membrane insertion. We hypothesized that if the above is true, BAX S184A should reconstitute membrane permeabilization independent of LUV diameter. As shown, BAX S184A synergized with BIM to permeabilize all LUV diameters with markedly increased efficiency compared to BAX WT ( Figures 7H, 7I , and S7D), indicating that after BAX a9 is mobilized, there are no further requirements for membrane diameter. Using 0.05 mm OMVs, we were able to corroborate that BAX S184A promotes membrane permeabilization and maintains the ability to associate with membranes similar to BAX WT and 1.0 mm OMVs ( Figures 7J, 7K , S7E, and S7F). Importantly, recombinant BAX S184A restored MOMP in permeabilized Mfn1 À/À MEFs treated with BIM, suggesting that our LUV and OMV studies are relevant in a cellular context ( Figures 7L and S7G) . Finally, to examine the function of BAX S184A in cellular responses to terminal UPR, we silenced endogenous Bax in Mfn1 À/À MEFs, reconstituted these cells with human BAX WT or BAX S184A
, treated with inducers of UPR, and compared the kinetics of cell death responses ( Figures 7M, S7H, and S7I ). As shown, Mfn1 À/À MEFs without BAX demonstrated minimal apoptotic responses, and the expression of BAX S184A was sufficient to promote apoptosis within the majority of cells, suggesting that once BAX a9 is mobilized, Mfn1-regulated mitochondrial shape no longer contributes to apoptosis (Figures 7M and S7I ).
DISCUSSION
Our work reveals that while proapoptotic BCL-2 proteins are induced following stress, the shape of the mitochondrial network dictates the functional cooperation among these proteins to 
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Mitochondrial Shape Governs BAX-Induced MOMP induce MOMP and apoptosis ( Figure 7N ). We thoroughly defined BCL-2 family requirements for tUPR using a panel of pharmacological agents in the setting of multiple MEFs genetically deficient for each subtype of the proapoptotic BCL-2 family ( Figures  1 and S1-S3) . Moreover, these studies provide a fresh perspective on integrating the role of mitochondrial shape with (D) LUVs were combined with BAX WT or BAX S184A for 30 min at 37 C.
(E) Same as in (D), but with BIM BH3 (2.5 mM).
(F) LUVs were combined with BAX WT or BAX S184A (100 nM) for 30 min at 37 C prior to centrifugation, solubilization, and western blot for associated BAX.
(G) NBD-BAX WT or NBD-BAX S184A was incubated with 1 mm LUVs for 5 min ± BIM BH3 (2.5 mM). An increase in NBD fluorescence indicates BAX$LUV interactions and is reported as fold increase compared to NBD-BAX WT + LUVs.
(H) LUVs (1 mm) were combined with BAX WT or BAX S184A (50, 75, 100 nM) with BIM BH3 (2.5 mM) for 30 min at 37 C.
(I) LUVs were combined with BAX WT or BAX S184A (50 nM) with BIM BH3 (2.5 mM) for 30 min at 37 C.
(J) OMVs were combined with BAX WT or BAX S184A (50 nM) and BIM BH3 (2.5 mM) for 30 min at 37 C.
(K) NBD-BAX WT or NBD-BAX S184A ± BIM BH3 (2.5 mM) was incubated with OMVs for 30 min at 37 C. The interaction between NBD-BAX WT + BIM BH3 with 1 mm
OMVs is reported as 100%. proapoptotic BCL-2 family function, as little is known about how BAX a9 is engaged and/or stably released from the BAX globular structure. We interpret the cellular data presented in Figure 3 to suggest that mitochondrial shape, and not necessarily Mfn1 per se, is a contributing regulator of tUPR-induced proapoptotic BCL-2 family function. This interpretation is supported by our biochemical experiments in Figures 5, 6, and 7 , where the extent of BAX$membrane association and OMV/LUV permeabilization are inversely proportionate to vesicle diameter. Indeed, our study provides a mechanistic understanding to a previous report that observed BAX membrane association and LUV size are related (Lucken-Ardjomande et al., 2008) . Taken into context, the present studies and literature reveal that at least three factors regulate BAX-mediated apoptosis: (1) a stressspecific combination of proapoptotic BH3-only proteins, (2) an OMM composition that is actively maintained and regulated by a host of lipid metabolic pathways, and (3) a particular mitochondrial shape that is consequential to the mitochondrial dynamics machinery, yet supports BAX membrane integration and pore formation (Beverly et al., 2013; Chipuk et al., 2010 Chipuk et al., , 2012 . Given that mitochondrial biology can vary between cell types, and that many pathophysiological conditions directly alter mitochondrial composition, it is not surprising that the regulatory mechanisms of BAX activation and apoptosis are complicated.
We previously published observations that support the current work, but from an alternative perspective. In Cassidy-Stone et al. (2008) , mDIVI-1 directly blocked the function of BAX to promote apoptosis in cells that have no apparent disruptions to the mitochondrial dynamics machinery. We interpret these results to suggest that when the mitochondrial dynamics machinery is functional, mDIVI-1 will hyperfuse the mitochondrial network leading to apoptotic resistance ( Figure 3K ). We suspect the same happens with OPA1 overexpression ( Figure S4Q ). Here, we utilized mDIVI-1 to correct a hyperfragmented state resulting from Mfn1 deficiency to regain a balanced mitochondrial network, and this led to apoptotic resensitization ( Figures  3C-3F and 3L-3N ). At the time of the original mDIVI-1 paper, a mechanistic role for DRP1 in BAX activation remained obscure. A few years later, Martinou and colleagues revealed that DRP1 could directly remodel the OMM and cause membrane hemifusion to promote BAX-dependent MOMP (Montessuit et al., 2010) . We speculate that similar to DRP1, Mfn1 may regulate mitochondrial network shape and potentially a currently unknown membrane phenotype that promotes productive interactions within the proapoptotic BCL-2 family. One long-standing question within the BCL-2 family literature is what distinguishes the OMM as the main target of proapoptotic BCL-2 function? These studies suggest that at least one factor is a biophysical aspect of the OMM's diameter and/or shape that supports BAX activation as perturbations of OMM diameter have significant influences on the BAX$membrane relationship ( Figure S7J) .
Finally, our work suggests that mitochondrial size and its relationship to the cellular decision to induce apoptosis is an overlooked contributing factor in multiple physiological and pathological scenarios. For example, mitochondrial fragmentation occurs during mitosis and is common in cancer, steatosis, and obesity. It is tempting to speculate that altering mitochondrial size is a cellular mechanism to transiently reduce MOMP, while long-term mitochondrial fragmentation could potentially lead to chemoresistance. Furthermore, it has been noted that tiny mitochondria resist MOMP and are required for mitochondrial repopulation and cellular survival following stress (Tait et al., 2010) . Gaining an integrated understanding of the cellular mediators for organelle communication, stress signaling, and the apoptotic machinery is critical to appreciate the mechanisms that control life and death decisions, along with improving the likelihood of discovering novel pharmacological targets to treat human disease.
EXPERIMENTAL PROCEDURES Reagents
All cell culture and transfection reagents were from Invitrogen, and standard reagents were from Sigma or Fisher Scientific unless indicated. The following drugs were purchased: ABT-737 (Abbott Pharmaceuticals), Hoechst 33342 (Anaspec), and b-ME, cisplatin, DTT, JC-1, mDIVI-1, Paclitaxel, Tg, TMRE, and Tun (Sigma). Antibodies (clone) are as follows: anti-actin (C4), anti-BCL-2 (100), anti-MCL-1 (Rockland), anti-BIM (22-40), anti-PUMA (CT; Sigma), anti-cytochrome c (7H8.2C12), anti-BAK (NT), anti-BAX (clone 6A7 for IP; clone N20 for western blot; clone D21 for trypsin studies), anti-BCL-xL (S18), anti-GAPDH (9B3), anti-Mfn1 (ABCAM, 57602), anti-Mfn2 (ABCAM, 56889), anti-HSP60 (B-9). BAX, BAX DC , BAX S184A , BCL-xL DC , N/C-BID, and BIM-S were made as described Suzuki et al., 2000; von Ahsen et al., 2000) . The human BIM and PUMA BH3 domain peptides (Abgent) were resuspended in anhydrous DMSO. Knockout and WT matched MEFs: Bak
À/À , and Mfn2 À/À were obtained from Drs. Stanley Korsmeyer (Wei et al., 2001 ), Doug Green , and Gerald Zambetti (Jeffers et al., 2003) and ATCC (Chen et al., 2003) .
Cell Culture and Apoptosis Assays
All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics. For cell death studies, cells were seeded for 24 hr and treated as described, and the floating and attached cells were harvested, stained with AnnexinV-FITC in binding buffer, and analyzed by flow cytometry as indicated (Logue et al., 2009) . For IncuCyte ZOOM experiments, cells were seeded in 48-well plates, treated as described in the presence of DRAQ7 (1.2 mM), imaged every hour, and reported as ±SE.
Mitochondrial Fractionation and Real-Time MOMP Measurements
Wild-type and Bak À/À liver mitochondrial fractions were isolated using trehalose isolation buffer (TIB), aliquoted (50 ml, 20 mg/ml), and stored at À80 C as described (Yamaguchi et al., 2007) . Mitochondria were rapidly thawed in a 30 C water bath, the volume was increased to 250 ml with TIB, and JC-1 was added to a final concentration of 15 mM, incubated for 10 min at 30 C, centrifuged (10 min at 5,500 3 g), and resuspended in 25 ml TIB. The suspension was applied to a 2 ml CL-2B column calibrated with TIB, and fractions (20 3 100 ml) were collected by gravity flow. Mitochondria-containing fractions were identified by testing each fraction (5 ml) with 0.1% Triton X-100 (95 ml) at 561 nm excitation and 620 nm emission. Related fractions were combined, and equivalent JC-1 relative fluorescent units were assayed per treatment using the indicated protein concentrations, as described (Ryan and Letai, 2013) . LUVs (0.05 and 1 mm) were fractionated using the same column, but with LUV buffer. For whole-cell studies, we employed a BH3-profiling protocol with 40,000 cells/well/96-well plate in 64 ml total reaction volumes, as described (Ryan and Letai, 2013 All data are representative of at least triplicate experiments, and reported as ± S.D., (or ± S.E. for IncuCyte) as required.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Animal studies. Mouse protocols were approved by the Icahn School of Medicine at Mount Sinai IACUC. 8 week-old male C57BL/6 mice (Charles River Breeding Laboratories) were housed under controlled temperature, humidity and light cycles (12h:12h). Standard chow diet and water were available ad libitum. To induce ER stress mice were injected i.p. with tunicamycin (Calbiochem Lot # D00127619; 2 mg/kg) or PBS control. 24 h after the injection mice were sacrificed by cervical dislocation, tissue was snap frozen in liquid nitrogen and stored at -80°C until further analysis.
Heavy membrane isolations. At least 2 × 15 cm dishes at 90 -95% confluency were used per treatment. Cells were harvested by trypsinization, and pelleted by centrifugation at 1000 × g for 10 minutes. The cell pellet was washed once with mitochondrial isolation buffer (MIB: 200 mM mannitol, 68 mM sucrose, 10 mM HEPES-KOH pH 7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.1% BSA), and resuspended in MIB supplemented with protease inhibitors (HALT, Pierce Biotechnology). The cell suspension was incubated on ice for 20 minutes, and homogenized using a 2 ml Potter-Elvehjem dounce.
The homogenate was centrifuged for 10 minutes at 800 × g at 4ºC, the supernatant collected, and centrifuged again using the same conditions to ensure that no unlysed cells or nuclei were present. The resulting supernatant was centrifuged for 10 minutes at 8000 × g at 4ºC. The supernatant was collected as the S8 cytosol; the pellet was collected as the heavy membrane fraction and lysed using RIPA buffer. For liver mitochondrial isolations, we employed a common protocol (Renault et al., 2013) .
Western blot analysis. Whole cell protein lysates were made from trypsinized cells, pelleted, resuspended in RIPA buffer supplemented with protease inhibitors, incubated on ice for 10 minutes and centrifuged for 10 minutes at 21,000 × g. Protein concentrations were determined by using a standard BCA kit and the lysates were then adjusted with RIPA buffer to equal the protein concentrations. Proteins (25-100 µg/lane) were subjected to SDS-PAGE before transferring to nitrocellulose by standard western conditions, blocked in 5% milk/TBST and primary antibodies (1:1000 in blocking buffer; incubated overnight at 4°C). The secondary antibody (1:5000 in blocking buffer) was incubated at 25°C for 1 hour before standard enhanced chemiluminescence detection.
For analysis from fresh liver, the tissue was homogenized in 20 mM MOPS, 2 mM EGTA, 5 mM EDTA, 30 mM sodium fluoride, 40 mM β-glycerophosphate, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 0.5% NP-40 and complete protease inhibitor cocktail (Roche) and centrifuged at 13,000 × g for 20 minutes at 4°C. Protein concentration in the supernatant was measured with a BCA protein quantification kit.
